Lundbeck instigates trials into AD treatment Lu AE58054

Lundbeck has announced the beginning of a trial into its Alzheimer’s disease (AD) augmentation treatment Lu AE58054.

The multi-centre, placebo-controlled, fixed-dose study of Lu AE58054 will examine the viability of using the treatment as an add-on to donepezil in patients with moderate AD.

Potent and selective 5-HT6-receptor antagonist Lu AE58054 may be effective in the treatment of disorders such as AD and schizophrenia, according to the firm.

Executive vice-president Anders Gersel Pedersen, head of drug development at Lundbeck, said: “We are very pleased that Lundbeck can continue to deliver projects that potentially can alter the course of this debilitating neurological disease and radically change the lives of patients.”

In early November, Lundbeck published its financial details for the third quarter of 2009, revealing that revenue for the period stood at 3.264 million Danish kroner (394.434 million pounds) – representing 20 per cent growth compared to 2008.